Summary: Asthma and chronic obstructive pulmonary disease (COPD) are among the most common chronic lung diseases in our clinical practice. During the COVID-19 pandemic, key questions relate to the risk of SARS-CoV-2 infection or a more severe course of the disease, and the safety of the drugs used (including inhaled glucocorticosteroids (ICS) in the treatment of patients with obstructive diseases. Elderly patients with COPD, severe asthma, and other chronic diseases may be at risk of being infected with SARS-CoV-2. Both international and national experts agree that all our patients with chronic lung diseases should be advised to continue their current treatment, including ICS. ICS have been shown to partially prevent or reduce the severity of exacerbation of asthma by reducing the level of ICAM-1 adhesin particles and other mechanisms important for modulating airway inflammation associated with viral infection. Treatment with drugs in the form of small-particle aerosols administered from dry powder (DPI) and pressure inhalers (pMDI) results in good deposition in the respiratory tract, and seems to be of particular importance in the era of COVID-19 pandemic and increased risk of loss of control by patients with respiratory diseases exposed to SARS-CoV-2 infection. In clinical practice, well-controlled asthma and COPD is associated with a reduction in the number of exacerbations, which is the primary goal of therapy in chronic lung diseases.